Journal of Shanghai Jiao Tong University (Medical Science) >

2022 , Vol. 42 >Issue 3: 375 - 380

DOI: https://doi.org/10.3969/j.issn.1674-8115.2022.03.017

Review

Review of the role of circulating exosomal microRNA in bronchial asthma

  • Yiting CHEN ,
  • Anda ZHAO ,
  • Rong LI ,
  • Wenhui KANG ,
  • Shenghui LI
Expand
  • 1.School of Public Health, Shanghai Jiao Tong University, Shanghai 200025, China
    2.Department of Nutrition, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China
LI Shenghui, E-mail: lsh9907@163.com.

Received date: 2021-10-25

  Online published: 2022-03-16

Supported by

National Natural Science Foundation of China(81874266)

Fold

Abstract

Bronchial asthma is a heterogeneous disease with complex pathological characteristics. At present, there is no sensitive and effective diagnostic method, and the severity is often underestimated, resulting in delayed treatment. Recently, circulating exosomal microRNAs (miRNAs) have been regarded as important communication mediators between cells. miRNAs are considered as potential disease biomarkers due to their high stability and convenience in specimen collection, as well as their high sensitivity and specificity in diagnosing and predicting various diseases. However, due to the late start of the research on circulating exosomal miRNAs, results on diagnosis, identification, efficacy prediction and prognosis evaluation of asthma are not consistent, and obstacles are still existing in its practical clinical application. Current evidence suggested that multiple circulating exosomal miRNAs could play a synergistic role in the occurrence and development of asthma, and individual physiological characteristics would be important factors affecting the association between circulating exosomal miRNAs and asthma. The differences and changes of the exact miRNA types and quantities before and after treatment in asthmatic patients with different disease progression and phenotypes need to be further refined and clarified. This review summarizes the recent advances in the association of circulating exosomal miRNAs with asthma, in terms of diagnoses, severity and phenotypic identifications, and curative effect and prognosis evaluations, in order to provide new ideas and directions for the early diagnosis and precise treatment of asthma.

Key words： exosome; circulating microRNA; asthma; biomarker

Cite this article

Yiting CHEN , Anda ZHAO , Rong LI , Wenhui KANG , Shenghui LI . Review of the role of circulating exosomal microRNA in bronchial asthma[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022 , 42(3) : 375 -380 . DOI: 10.3969/j.issn.1674-8115.2022.03.017

References

1 MACIAG M C, PHIPATANAKUL W. Prevention of asthma: targets for intervention[J]. Chest, 2020, 158(3): 913-922.
2 PAPI A, BRIGHTLING C, PEDERSEN S E, et al. Asthma[J]. Lancet, 2018, 391(10122): 783-800.
3 AARON S D, BOULET L P, REDDEL H K, et al. Underdiagnosis and overdiagnosis of asthma[J]. Am J Respir Crit Care Med, 2018, 198(8): 1012-1020.
4 CA?AS J A, SASTRE B, RODRIGO-MU?OZ J M, et al. Exosomes: a new approach to asthma pathology[J]. Clin Chim Acta, 2019, 495: 139-147.
5 STOLZENBURG L R, HARRIS A. The role of microRNAs in chronic respiratory disease: recent insights[J]. Biol Chem, 2018, 399(3): 219-234.
6 李想, 尚云晓. 外泌体及其微小RNA在哮喘中的研究进展[J]. 国际儿科学杂志, 2019, 46(12): 901-906.
7 GUO Y, JI X, LIU J, et al. Effects of exosomes on pre-metastatic niche formation in tumors[J]. Mol Cancer, 2019, 18(1): 39.
8 LU T X, ROTHENBERG M E. MicroRNA[J]. J Allergy Clin Immunol, 2018, 141(4): 1202-1207.
9 MITCHELL P S, PARKIN R K, KROH E M, et al. Circulating microRNAs as stable blood-based markers for cancer detection[J]. Proc Natl Acad Sci U S A, 2008, 105(30): 10513-10518.
10 FEHLMANN T, KAHRAMAN M, LUDWIG N, et al. Evaluating the use of circulating microRNA profiles for lung cancer detection in symptomatic patients[J]. JAMA Oncol, 2020, 6(5): 714-723.
11 SUN Z, SHI K, YANG S, et al. Effect of exosomal miRNA on cancer biology and clinical applications[J]. Mol Cancer, 2018, 17(1): 147.
12 RAMSAHAI J M, HANSBRO P M, WARK P A B. Mechanisms and management of asthma exacerbations[J]. Am J Respir Crit Care Med, 2019, 199(4): 423-432.
13 ISHMAEL F T, CRAIG T J, AUGUST A, et al. Circulating micro-RNAs are biomarkers and potential therapeutic targets in asthma[J]. J Allergy Clin Immunol, 2015, 135(2): AB162.
14 王湘云, 陈乾, 孙亚红, 等. 不同严重程度哮喘患者血清外泌体中微RNA-21的表达水平及其诊断价值[J]. 第二军医大学学报, 2018, 39(7): 740-744.
15 ATASHBASTEH M, MORTAZ E, MAHDAVIANI S A, et al. Expression levels of plasma exosomal miR-124, miR-125b, miR-133b, miR-130a and miR-125b-1-3p in severe asthma patients and normal individuals with emphasis on inflammatory factors[J]. Allergy Asthma Clin Immunol, 2021, 17(1): 51.
16 BAHMER T, KRAUSS-ETSCHMANN S, BUSCHMANN D, et al. RNA-seq-based profiling of extracellular vesicles in plasma reveals a potential role of miR-122-5p in asthma[J]. Allergy, 2021, 76(1): 366-371.
17 ROSTAMI HIR S, ALIZADEH Z, MAZINANI M, et al. Exosomal microRNAs as biomarkers in allergic asthma[J]. Iran J Allergy Asthma Immunol, 2021, 20(2): 160-168.
18 HUANG Y, ZHANG S, FANG X, et al. Plasma miR-199a-5p is increased in neutrophilic phenotype asthma patients and negatively correlated with pulmonary function[J]. PLoS One, 2018, 13(3): e0193502.
19 ELBEHIDY R M, YOUSSEF D M, EL-SHAL A S, et al. MicroRNA-21 as a novel biomarker in diagnosis and response to therapy in asthmatic children[J]. Mol Immunol, 2016, 71: 107-114.
20 王静, 赵怡然, 刘晓佳, 等. 哮喘患儿血清外泌体中miR-7b表达变化及其临床意义[J]. 山东医药, 2020, 60(34): 88-91.
21 NAIR P, PRABHAVALKAR K S. Neutrophilic asthma and potentially related target therapies[J]. Curr Drug Targets, 2020, 21(4): 374-388.
22 ZHAO M, JUANJUAN L, WEIJIA F, et al. Expression levels of microRNA-125b in serum exosomes of patients with asthma of different severity and its diagnostic significance[J]. Curr Drug Metab, 2019, 20(10): 781-784.
23 RIAL M J, RODRIGO-MU?OZ J M, SASTRE B, et al. Stability of asthma control implies no changes in microRNAs expression[J]. J Investig Allergol Clin Immunol, 2019, 29(5): 388-389.
24 WEIDNER J, EKERLJUNG L, MALMH?LL C, et al. Circulating microRNAs correlate to clinical parameters in individuals with allergic and non-allergic asthma[J]. Respir Res, 2020, 21(1): 107.
25 WARDZY?SKA A, PAWE?CZYK M, RYWANIAK J, et al. Circulating miRNA expression in asthmatics is age-related and associated with clinical asthma parameters, respiratory function and systemic inflammation[J]. Respir Res, 2021, 22(1): 177.
26 KHO A T, SHARMA S, DAVIS J S, et al. Circulating microRNAs: association with lung function in asthma[J]. PLoS One, 2016, 11(6): e0157998.
27 HUAN T X, CHEN G, LIU C Y, et al. Age-associated microRNA expression in human peripheral blood is associated with all-cause mortality and age-related traits[J]. Aging Cell, 2018, 17(1): e12687.
28 RIAL M J, CA?AS J A, RODRIGO-MU?OZ J M, et al. Changes in serum microRNAs after anti-IL-5 biological treatment of severe asthma[J]. Int J Mol Sci, 2021, 22(7): 3558.
29 TAKA S, TZANI-TZANOPOULOU P, WANSTALL H, et al. MicroRNAs in asthma and respiratory infections: identifying common pathways[J]. Allergy Asthma Immunol Res, 2020, 12(1): 4-23.
30 WARDZY?SKA A, PAWE?CZYK M, RYWANIAK J, et al. Circulating microRNAs and T-cell cytokine expression are associated with the characteristics of asthma exacerbation[J]. Allergy Asthma Immunol Res, 2020, 12(1): 125-136.
31 HAN J, ZHAO F, ZHANG J, et al. miR-223 reverses the resistance of EGFR-TKIs through IGF1R/PI3K/Akt signaling pathway[J]. Int J Oncol, 2016, 48(5): 1855-1867.
32 CHEN JJ, OUYANG H, AN X M, et al. miR-125a is upregulated in cancer stem-like cells derived from TW01 and is responsible for maintaining stemness by inhibiting p53[J]. Oncol Lett, 2019, 17(1): 87-94.
33 UDDIN M A, BARABUTIS N. P53 in the impaired lungs[J]. DNA Repair, 2020, 95: 102952.
34 TRIAN T, ALLARD B, OZIER A, et al. Selective dysfunction of p53 for mitochondrial biogenesis induces cellular proliferation in bronchial smooth muscle from asthmatic patients[J]. J Allergy Clin Immunol, 2016, 137(6): 1717-1726.e13.
35 DING Y, HOU Y, LIU Y, et al. Prospects for miR-21 as a target in the treatment of lung diseases[J]. Curr Pharm Des, 2021, 27(3): 415-422.
36 JIANG C, GUO Y, YU H, et al. Pleiotropic microRNA-21 in pulmonary remodeling: novel insights for molecular mechanism and present advancements[J]. Allergy Asthma Clin Immunol, 2019, 15: 33.
37 LIU J H, LI C, ZHANG C H, et al. LncRNA-CASC7 enhances corticosteroid sensitivity via inhibiting the PI3K/AKT signaling pathway by targeting miR-21 in severe asthma[J]. Pulmonology, 2020, 26(1): 18-26.
38 DOUGHERTY E J, ELINOFF J M, FERREYRA G A, et al. Mineralocorticoid receptor (MR) trans-activation of inflammatory AP-1 signaling: dependence on DNA sequence, MR conformation, and AP-1 family member expression[J]. J Biol Chem, 2016, 291(45): 23628-23644.
39 WANG J, HE F, CHEN L, et al. Resveratrol inhibits pulmonary fibrosis by regulating miR-21 through MAPK/AP-1 pathways[J]. Biomed Pharmacother, 2018, 105: 37-44.
40 LI J C, HUANG L X, HE Z N, et al. Andrographolide suppresses the growth and metastasis of luminal-like breast cancer by inhibiting the NF-κB/miR-21-5p/PDCD4 signaling pathway[J]. Front Cell Dev Biol, 2021, 9: 643525.
Options
Outlines

/

〈 〉